Embla Medical
| Date: | 18.6.2025 |
|---|---|
| Country: | Iceland |
| Customer: | Embla Medical |
| Amount in EUR: | EUR 50 million |
| Maturity: | 7 years |
| Business sector: | Connectivity & Consumer |
Project
The loan has been provided for Embla Medical to finance the company’s research and development (R&D) programme. The loan supports Embla’s mission to develop innovative medical solutions that enhance mobility and quality of life for people living with limb loss or mobility impairments.
Embla’s R&D programme focuses on developing cutting-edge technologies in prosthetics and bracing and support solutions. Embla will keep expanding its portfolio, with R&D activities centred at its Reykjavik facility.
Fulfilment of NIB's mandate
Productivity:
The NIB financed R&D programme is expected to drive productivity growth of the company and it can affect the productivity of other companies operating in the same industry or region as well through knowledge spillovers.
Investments in high value-added operations and skills in the company’s headquarters supports valuable diversification of economic activities in Iceland.
Ex-ante Productivity Impact Indicators:
- R&D intensity (2024–2028): 8%
- R&D expenditures (2023): USD 37 million
- R&D expenditures (2026): USD 49 million
- New product launches: 15
- Registered patents: 2,000
Environment:
No environmental benefits expected from the R&D programme.
Sustainability summary
No significant negative aspects associated with the R&D programme.
